Invasive Pulmonary Aspergillosis Complicating Influenza Infection

Universitaire Ziekenhuizen KU Leuven298 enrolled

Overview

Study the incidence and outcome of invasive pulmonary aspergillosis (IPA) in ICU patients with severe influenza and in influenza-negative control patients with severe community-acquired pneumonia

This prospective multicentre case-control registration study in Dutch and Belgian ICUs will assess the difference in incidence and outcome of invasive pulmonary aspergillosis (IPA) in ICU patients with severe influenza compared with influenza-negative control patients with severe community-acquired pneumonia during the coming three influenza seasons (2017-2020). The study will further assess the differences in clinical characteristics and risk factors between influenza patients with and without invasive aspergillosis. All consecutive patients aged 18 or older admitted to ICU during the inclusion period with respiratory distress due to influenza positive/negative community acquired pneumonia (CAP) will be included.

Study Type

OBSERVATIONAL

Enrollment

298

Conditions

Influenza With Pneumonia Aspergillosis Invasive

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient older than 18 years,admitted to ICU with respiratory distress with microbiologically confirmed diagnosis of influenza (for inclusion in the influenza group) * patients older than 18 years, admitted to ICU for respiratory distress due to community-acquired pneumonia , with a microbiologically confirmed absence of influenza (for inclusion in the control group) Exclusion Criteria: * age \< 18 year * no informed consent

Locations (2)

AZ sint Jan

Bruges, Belgium

Jessa AH

Hasselt, Belgium

Outcomes

Primary Outcomes

incidence IPA between ICU patients with severe influenza and in influenza-negative control patients

incidence of mycological evidence of Aspergillus and at least one Aspergillus compatible sign or symptom and radiological abnormalities based on Chest CT or Chest X ray. Mycological evidence can be provided by either (A) a positive culture of Aspergillus cultured from bronchoalveolar lavage (BAL) sample, (B) ≥2 positive cultures of Aspergillus cultured from a sputum or a bronchial aspirate or (C) a galactomannan (GM) optical density of ≥1 in BAL or ≥0.5 in serum. Aspergillus compatible signs or symptoms are defined as at least one of the following: * Worsening respiratory insufficiency in spite of proper antibiotic and ventilator support * Dyspnea * Haemoptysis * Fever refractory to at least 3 days of appropriate antibiotic (AB) therapy. Recrudescent fever after a period of defervescence of at least 48 h while still on AB without apparent cause. The presence of hyphae in lung biopsy or autopsy are also considered as sufficient evidence for IPA.

Time frame: from date of admission in ICU assessed up to ICU discharge, approximately 21 days

Secondary Outcomes

variations in baseline factors and risk factors between influenza and non-influenza patients in ICU

difference in baseline factors: demographic, biochemical, microbiological and radiological data

Time frame: from date of admission in ICU to date of ICU discharge, approximately 21 days

rate of IPA disease progression

rate of IPA disease progression in the subgroup of patients with IPA

Time frame: from date of admission to ICU to date of discharge from ICU, approximately 21 days

rate of presence of azole resistance

rate of presence of azole resistance in the subgroup of patients with IPA

Time frame: from date of admission to ICU to date of discharge from ICU, approximately 21 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.